BDX
Stock Details
BDX is Becton, Dickinson and Company's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 257.94$. Average daily volumn in 3 months 1.26M. Market cap 71.92B
Stock symbol : BDX. Exchange : NYSE. Currency : USD Lastest price : 252.30$. Total volume : 910.92k. Market state POSTPOST Click reload if you want to check the lastest price on market!!!
Becton, Dickinson and Company (BDX)
Last Price
252.30$Change
1.16Volume
910.92k
| Previous Close | 251.14 |
| Open | 252.40 |
| Day Range | 247.82-253.40 |
| Bid | 247.67 x 900 |
| Ask | 257.08 x 1.8k |
| Volume | 910.92k |
| Average Volume | 1.26M |
| Market Cap | 71.92B |
| Beta | 0.66 |
| 52 Week Range | 229.40-277.29 |
| Trailing P/E | 39.83 |
| Foward P/E | 20.56 |
| Dividend (Yield %) | 1.39% |
| Ex-Dividend Date | 2022-06-08 |
Financial Details
Organization
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and ... extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Market Cap:
71.92BRevenue:
20.25BTotal Assets:
53.87BTotal Cash:
2.28B
News about "Becton, Dickinson and Company"
SVB Leerink Comments on Becton, Dickinson and Company’s FY2022 Earnings (NYSE:BDX)
Source from : Defense World - 12 days ago
SVB Leerink lowered their FY2022 EPS estimates for shares of Becton, Dickinson and in a research note issued on Thursday, May 5th. SVB Leerink analyst D. Antalffy now forecasts that the medical ...See details»
Becton, Dickinson and Company (NYSE:BDX) Given Consensus Recommendation of “Hold” by Analysts
Source from : Defense World - 12 days ago
Becton, Dickinson and Company (NYSE:BDX – Get Rating) has received a consensus rating of “Hold” from the ten analysts that are currently covering the firm, Marketbeat reports. Six research analysts ...See details»
StockNews.com Upgrades Becton, Dickinson and (NYSE:BDX) to Buy
Source from : ETF Daily News - 7 days ago
Becton, Dickinson and (NYSE:BDX – Get Rating) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a report issued on Saturday. Several other brokerages have also issued reports on ...See details»
Becton, Dickinson and (NYSE:BDX) Updates FY 2022 Earnings Guidance
Source from : ETF Daily News - 4 days ago
Becton, Dickinson and (NYSE:BDX – Get Rating) updated its FY 2022 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of $11.15-$11.30 for the period, compared to the ...See details»
Becton, Dickinson and Company (BDX) CEO Tom Polen on Q2 2022 Results - Earnings Call Transcript
Source from : Seeking Alpha - 15 days ago
Q2 2022 Earnings Conference Call May 05, 2022, 08:00 AM ET Company Participants Francesca DeMartino - SVP, IR Tom Polen - President, CEO ...See details»
Becton, Dickinson and Co - Stock Quote 0R19
Source from : Morningstar%2c Inc. - 25 days ago
There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible ...See details»
Becton, Dickinson and Company Q2 Profit Increases, beats estimates
Source from : Business Insider - 15 days ago
(RTTNews) - Becton, Dickinson and Company (BDX) revealed earnings for its second quarter that increased from last year and beat the Street estimates. The company's bottom line totaled $431 million ...See details»
Becton, Dickinson and Company: Despite Lower COVID-19 Testing and Tough Comparables, Becton, Dickinson Continues to Grow
Source from : Yahoo Finance - 16 days ago
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic ...See details»
Becton, Dickinson And Co. Lifts FY22 Outlook - Update
Source from : Business Insider - 15 days ago
While announcing higher second-quarter results on Thursday, medical technology company Becton, Dickinson and Co. (BDX) raised the ...See details»
Client Profile: Becton, Dickinson & Co
Source from : OpenSecrets.org - 29 days ago
A special interest's lobbying activity may go up or down over time, depending on how much attention the federal government is giving their issues. Particularly active clients often retain multiple ...See details»
Blood Collection Tubes Market to Observe Exponential Growth By 2022 to 2028 | Becton, Dickinson and Company, QIAGEN
Source from : Digital Journal - 1 days ago
Becton, Dickinson and Company, Greiner Bio-One International GmbH, QIAGEN, McKesson Medical-Surgical Inc., FL MEDICAL s.r.l., Haemonetics Corporation, AdvaCare Pharmaceuticals, Sarstedt AG & Co., ...See details»
Becton Dickinson ordered to pay $255k in hernia mesh trial
Source from : Reuters - 1 month ago
Plaintiff alleged infection, abscess caused by defective mesh implant Company still faces more than 26,000 hernia mesh claims in federal and state court The company and law firm names shown above ...See details»
Becton Dickinson: Fiscal Q2 Earnings Snapshot
Source from : Greenwich Time - 15 days ago
FRANKLIN LAKES, N.J. (AP) _ Becton Dickinson and Co. (BDX) on Thursday reported fiscal second-quarter profit of $454 million. The Franklin Lakes, New Jersey-based company said it had profit of $1 ...See details»
Becton Dickinson and Co
Source from : MSN - 16 days ago
Chairman of the Board, President, Chief Executive Officer, Chief Operating Officer Christopher DelOrefice Chief Financial Officer, Executive Vice President David Hickey +401.10 ...See details»